Edition:
India

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

1.94USD
22 Mar 2019
Change (% chg)

$0.01 (+0.52%)
Prev Close
$1.93
Open
$1.93
Day's High
$1.96
Day's Low
$1.87
Volume
26,971
Avg. Vol
50,587
52-wk High
$9.13
52-wk Low
$0.52

Summary

Name Age Since Current Position

Jeffrey Bailey

56 2018 Chairman of the Board

Manuel Aivado

48 2018 President, Chief Executive Officer, Director

Donald Dougherty

59 2017 Senior Vice President, Chief Financial Officer

D. Allen Annis

2018 Senior Vice President - Research

Kira Nelson

49 2015 Vice President - Finance, Vice President - Operations

Vojislav Vukovic

2018 Chief Medical Officer

Reinhard Ambros

64 2013 Independent Director

John McArthur

84 2011 Independent Director

Jodie Morrison

42 2017 Independent Director

Armen Shanafelt

59 2013 Independent Director

Caleb Winder

46 2014 Independent Director

Biographies

Name Description

Jeffrey Bailey

Mr. Jeffrey A. Bailey is Chairman of the Board of the Company. Mr. Bailey has served as chair of our board of directors and as a member of our board of directors since March 2018. Since January 2018, Mr. Bailey has served as chief executive officer and director of IlluminOss Medical, Inc., a medical device company. From December 2015 until March 2017, Mr. Bailey served as chairman and chief executive officer of Neurovance, Inc., a biotechnology firm acquired by Otsuka Pharmaceutical in 2017. Previously, from January 2013 through June 2015, Mr. Bailey served as president and chief executive officer and as a director of Lantheus Medical Imaging, Inc., a public medical diagnostic company. Prior to 2013, Mr. Bailey held various leadership positions with several public and private pharmaceutical and medical device companies, including operating unit president at Novartis Pharmaceuticals, a multinational pharmaceutical company, and a 22-year career with Johnson & Johnson, multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company (including Janssen Pharmaceutica NV). Mr. Bailey has also served as a director of Madison Vaccines, Inc., a biopharmaceutical company, since October 2017. Mr. Bailey received a B.S. from Rutgers University.

Manuel Aivado

Mr. Manuel C. Aivado is President, Chief Executive Officer, Director of the Company. He has served as our Senior Vice President, Chief Medical Officer since September 2014. From March 2012 until September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 until March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. In addition, Dr. Aivado was an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for nearly ten years, during which time he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology and medical oncology, and he received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany. The Company believes that Dr. Aivado is qualified to serve on its Board due to his extensive knowledge of the Company and his significant background in pharmaceutical research and development.

Donald Dougherty

Mr. Donald V. Dougherty is a Senior Vice President and Chief Financial Officer of the company. He has served as our senior vice president, chief financial officer since June 2017. Mr. Dougherty founded Compound Capital Growth Investments, LLC, a Boston investment firm focused on biopharmaceutical and other technology sectors, and served as its president from November 1999 to June 2017. Previously, Mr. Dougherty held senior positions at Essex Investment Management, where he was a principal, portfolio manager and lead biotechnology analyst, and Putnam Investments, where he was a senior vice president and analyst in the Specialty Growth Group. Mr. Dougherty received a B.A. from Williams College and a M.B.A. from New York University.

D. Allen Annis

Dr. D. Allen Annis, Ph.D. is the Vice President - Biophysical and Analytical Technologies of Aileron Therapeutics, Inc. He has served as our Senior Director of Biophysical and Analytical Technologies since November of 2007. He was previously Director of Technology Development at the Schering-Plough Research Institute in Cambridge, MA, and prior to that he was Vice President of New Technologies at NeoGenesis Pharmaceuticals, which was acquired by Schering in 2005. While at NeoGenesis, Dr. Annis co-developed its core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System (ALIS). Dr. Annis authored several patents and publications that describe the ALIS technology, and invented many novel techniques that use ALIS to study protein-drug interactions. Dr. Annis received his B.S. in chemistry from the Georgia Institute of Technology and received his Ph.D. in chemistry from Harvard University.

Kira Nelson

Ms. Kira A. Nelson is the Vice President - Finance and Operations of the company. He has served as our vice president, finance and operations since April 2015. From February 2013 to April 2015, Ms. Nelson served as our Director of Accounting and Finance. From March 2002 to February 2013, Ms. Nelson was a finance and accounting consultant to companies in various industries, including biotechnology, providing accounting and finance services. From 1998 to March 2002, Ms. Nelson held various positions at Omtool, Ltd., a developer of software solutions, ultimately serving as chief financial officer, secretary and treasurer. From 1997 to 1998, Ms. Nelson served as a senior financial analyst at Discreet Logic. Ms. Nelson began her career at Arthur Andersen LLP, where she became a certified public accountant. Ms. Nelson received a B.A. from the College of the Holy Cross.

Vojislav Vukovic

Mr. Vojislav Vukovic is Chief Medical Officer of the Company. Dr. Vukovic is a pharmaceutical industry executive with 20 years of hands-on experience in oncology drug development and medical affairs. Most recently, he was the CMO of Taiho Oncology, where he oversaw the reorganization and scaling of the U.S. and European R&D function to advance the development of the company's clinical programs. Prior to Taiho, Dr. Vukovic held the CMO role at Synta Pharmaceuticals Inc. where he oversaw the company's clinical programs, as well as biometrics, clinical operations, pharmacovigilance, regulatory and medical affairs. During his tenure at Synta, Dr. Vukovic led many early and late-stage clinical trials and their translational research activities, including biomarker discovery and validation. Prior to Synta, Dr. Vukovic was a Medical Director at Pfizer, where he was responsible for the development of sunitinib and axitinib in several oncology indications. He also was a member of the leadership team for Pfizer's Oncology Radiotherapy Initiative.

Reinhard Ambros

Dr. Reinhard J. Ambros, Ph.D. is the Independent Director of the Company. He has served as a member of our board of directors since June 2013. From August 2005 until September 2017, Dr. Ambros served as global head of Novartis Venture Funds. He previously served as head of group strategic planning for Novartis AG, a multinational pharmaceutical company, from 2001 until 2005, and as global head of business development and licensing for cardiovascular and metabolic diseases at Novartis Pharma AG. Dr. Ambros received an M.S. from the University of Regensburg, Germany, and a Ph.D. in medicinal chemistry and pharmacology from the University of Regensburg, Germany. We believe Dr. Ambros is qualified to serve on our board of directors due to his management experience in the biotechnology sector and his service on other boards of directors.

John McArthur

Dr. John H. McArthur, D.B.A. is the Independent Director of the company. He has served as a member of our board of directors since April 2011. Since 1995, Dr. McArthur has served as the George F. Baker professor of business administration emeritus and dean emeritus at Harvard Business School. From 1980 until 1995, he served as dean of the faculty at Harvard Business School. Prior to that, Dr. McArthur was a member of the faculty at Harvard Business School since 1962. Since 1999, Dr. McArthur has served as a member of the board of directors of Koç Holding, A.S., a multinational industrial conglomerate. From 1995 to 2005, Dr. McArthur served as senior advisor to the president of The World Bank. Dr. McArthur formerly served as chair of Brigham and Women’s Hospital. He received a B.C. from the University of British Columbia and an M.B.A. and D.B.A from Harvard Business School.

Jodie Morrison

Ms. Jodie P. Morrison is the Independent Director of the company. She has served as a member of our board of directors since June 2017. From September 2017 until November 2017, Ms. Morrison served as president and chief executive officer of eGenesis, Inc., a private life sciences company. Since May 2017, Ms. Morrison has provided independent consulting services to venture capital, biotechnology and pharmaceutical companies. Previously, Ms. Morrison served as the president and chief executive officer of Tokai Pharmaceuticals, Inc, now Novus Therapeutics, Inc., or Novus, a biopharmaceutical company, from March 2013 until May 2017. From December 2006 until March 2013, Ms. Morrison held other senior positions with Novus, including chief operating officer, head of clinical affairs and program operations and vice president of clinical affairs and program operations. Prior to joining Novus, Ms. Morrison served as director of clinical operations and medical affairs at Dyax Corporation, or Dyax. Prior to joining Dyax, Ms. Morrison held clinical management positions at both Curis, Inc. and at Diacrin, Inc. Ms. Morrison has served as a member of the board of directors of Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, since June 2016 and Novus since March 2013. Ms. Morrison received a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from the Boston University School of Medicine and her business training through the Greater Boston Executive Program at the MIT Sloan School of Management.

Armen Shanafelt

Dr. Armen B. Shanafelt, Ph.D. is the Independent Director of the company. he has served as a member of our board of directors since November 2013. Since April 2009, he has served as a partner at Lilly Ventures, one of the venture capital arms of Eli Lilly and Company, a global pharmaceutical company. Prior to joining Lilly Ventures, Dr. Shanafelt served as the chief scientific officer of the biotechnology division at Eli Lilly and Company. Prior to joining Eli Lilly, he was a research fellow and director of research at Roche Diagnostics Corporation, a global diagnostics company, and held several leadership positions in the biotechnology division at Bayer Corporation, a multinational chemical and healthcare corporation. Dr. Shanafelt currently serves on the board of directors of three public biopharmaceutical companies, Aeglea BioTherapeutics, Inc., Protagonist Therapeutics, Inc. and Surface Oncology, Inc. Dr. Shanafelt received a B.S. from Pacific Lutheran University and a Ph.D. from the University of California, Berkeley.

Caleb Winder

Mr. Caleb Winder is the Independent Director of the company. he has served as a member of our board of directors since December 2014. He has served as a managing director of Excel Venture Management, or Excel, a venture capital firm that focuses on life science technologies, since March 2014, served as a director of Excel from November 2010 to February 2014, and served as vice president of Excel from January 2007 to October 2010. Prior to this, Mr. Winder was a principal at Biotechonomy, a life sciences research and investment firm, where he financed and managed several entrepreneurial ventures. Mr. Winder received a B.A. from Colby College and an M.B.A. from Babson College. We believe Mr. Winder is qualified to serve on our board of directors due to his investment experience in the life sciences sector.